NYSE American: NNVC

NanoViricides (NYSE American:NNVC) Bolsters Partnership Efforts – Engages Aagami Inc.

SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for our assets and platform technology. The Company is currently seeking licensing and partnering opportunities for […]

Lethally RSV Infected Animals Orally Treated with NV-387 (NYSE American:NNVC) Showed Normal Lung Histology, Indicating Potential Cure

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related […]

NanoViricides (NYSE American:NNVC) Has Filed its Quarterly Report

NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with […]

NanoViricides (NYSE Amer.:NNVC)A Novel Broad-Spectrum Antiviral with Activity Against RSV

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally […]

NanoViricides (NYSE American:NNVC) to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President and Executive Chairman, will be attending the EF Hutton Annual Global Conference, which will be held at The Plaza Hotel in New York, NY […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.